SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

EssilorLuxottica S.A. ESLOY OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • FR • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

EssilorLuxottica S.A. (ESLOY) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $120.76. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $27.4B, +3.8%/yr average growth. Net income is $2.2B, growing at +1.2%/yr. Net profit margin is 8.1% (thin). Gross margin is 60.6% (-3.1 pp trend).

Balance sheet: total debt is $17.0B against $38.9B equity (Debt-to-Equity (D/E) ratio 0.44, conservative). Current ratio is 0.99 (tight liquidity). Debt-to-assets is 26.7%. Total assets: $63.9B.

Analyst outlook: 0 / 1 analysts rate ESLOY as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 45/100 (Partial), Past 100/100 (Pass), Health 67/100 (Partial), Moat 81/100 (Pass), Future 20/100 (Fail), Income 45/100 (Partial).

ESLOY SharesGrow Score Overview

53/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 45/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 81/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ESLOY

ESLOY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ESLOY: +3.8%/yr revenue is, +1.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

ESLOY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet ESLOY: Debt-to-Equity (D/E) ratio 0.44 (conservative), Current ratio is 0.99 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ESLOY: Gross margin is 60.6% (-3.1 pp trend), $111B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 81/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate ESLOY as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ESLOY: Net profit margin is 8.1%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range109-186.81

Volume7.95K

Avg Volume (30D)122.14K

Market Cap$111.1B

Beta (1Y)0.61

Dividend Yield$2.2498

Share Statistics

EPS (TTM)2.42

Shares Outstanding$918.04M

IPO Date2008-01-30

Employees153,498

CEOFrancesco Milleri

Financial Highlights & Ratios

Revenue (TTM)$27.37B

Gross Profit$16.57B

EBITDA$6.22B

Net Income$2.22B

Operating Income$3.23B

Total Cash$3.54B

Total Debt$17.04B

Net Debt$13.5B

Total Assets$63.87B

Price / Earnings (P/E)49.9

Price / Sales (P/S)4.06

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryFR

ExchangeOther OTC

CurrencyUSD

ISINUS2972842007

Price Chart

ESLOY

EssilorLuxottica S.A. ↗ · Other OTC

Healthcare • Medical - Instruments & Supplies

109.00 52WK RANGE 186.81

People Also View

EssilorLuxottica SA

HOYA Corporation

Becton, Dickinson and Company

Straumann Holding AG

Sysmex Corporation

Carl Zeiss Meditec AG

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message